Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of ALLO-ASC-DFU in Diabetic Foot Ulcers
NCT02394886Phase 1Completed
- Sponsor
- Anterogen Co., Ltd.
- Start
- Nov 2014
- Primary completion
- May 2015
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of allo-asc in diabetic foot ulcer (DFU), sponsored by Anterogen Co., Ltd. Primary endpoint: Number of Participants with Adverse Events as a Measure of Safety and Tolerability at 4 weeks. Started Nov 2014; status: completed.
02
Drugs
allo-asc
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on NCT02394886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02394886.